AU2012205601B2 - Combination - Google Patents

Combination Download PDF

Info

Publication number
AU2012205601B2
AU2012205601B2 AU2012205601A AU2012205601A AU2012205601B2 AU 2012205601 B2 AU2012205601 B2 AU 2012205601B2 AU 2012205601 A AU2012205601 A AU 2012205601A AU 2012205601 A AU2012205601 A AU 2012205601A AU 2012205601 B2 AU2012205601 B2 AU 2012205601B2
Authority
AU
Australia
Prior art keywords
compound
administered
methyl
chloro
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012205601A
Other languages
English (en)
Other versions
AU2012205601A1 (en
Inventor
Rakesh Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012205601A1 publication Critical patent/AU2012205601A1/en
Application granted granted Critical
Publication of AU2012205601B2 publication Critical patent/AU2012205601B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012205601A 2011-01-11 2012-01-11 Combination Ceased AU2012205601B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
US61/431,508 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (2)

Publication Number Publication Date
AU2012205601A1 AU2012205601A1 (en) 2013-08-01
AU2012205601B2 true AU2012205601B2 (en) 2016-03-24

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012205601A Ceased AU2012205601B2 (en) 2011-01-11 2012-01-11 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (https=)
EP (1) EP2663189B1 (https=)
JP (1) JP6100700B2 (https=)
KR (1) KR20140053836A (https=)
CN (1) CN103298345B (https=)
AU (1) AU2012205601B2 (https=)
BR (1) BR112013017722A2 (https=)
CA (1) CA2824201A1 (https=)
EA (1) EA029000B1 (https=)
ES (1) ES2689760T3 (https=)
IL (1) IL227097B (https=)
MX (1) MX356704B (https=)
SG (2) SG191724A1 (https=)
WO (1) WO2012097021A1 (https=)
ZA (1) ZA201304139B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197754A1 (en) * 2009-01-30 2010-08-05 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
WO2005095387A1 (en) * 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
EP2708531A1 (en) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
AU2007234379A1 (en) 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
MY149140A (en) 2006-10-13 2013-07-15 Basf Se Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
BR112012008274A2 (pt) 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
WO2012151413A1 (en) 2011-05-03 2012-11-08 University Of Rochester Methods for treating prostate cancer
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
RS55223B1 (sr) 2011-10-10 2017-02-28 Zach System Postupak za dobijanje 17-supstituisanih steroida
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197754A1 (en) * 2009-01-30 2010-08-05 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride

Also Published As

Publication number Publication date
EA201391027A1 (ru) 2014-01-30
EP2663189B1 (en) 2018-07-04
CN103298345A (zh) 2013-09-11
JP2014507412A (ja) 2014-03-27
US20130288984A1 (en) 2013-10-31
WO2012097021A1 (en) 2012-07-19
SG10201600077RA (en) 2016-02-26
MX356704B (es) 2018-06-11
AU2012205601A1 (en) 2013-08-01
US20160022641A1 (en) 2016-01-28
IL227097B (en) 2018-02-28
CN103298345B (zh) 2016-12-14
JP6100700B2 (ja) 2017-03-22
KR20140053836A (ko) 2014-05-08
EA029000B1 (ru) 2018-01-31
EP2663189A4 (en) 2014-06-11
SG191724A1 (en) 2013-08-30
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
BR112013017722A2 (pt) 2016-07-12
US10449226B2 (en) 2019-10-22
ZA201304139B (en) 2014-02-26
CA2824201A1 (en) 2012-07-19
US20120258933A1 (en) 2012-10-11
MX2013008074A (es) 2013-08-09
US20170100449A1 (en) 2017-04-13
US20150119337A1 (en) 2015-04-30
US20160375086A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
AU2012205601B2 (en) Combination
AU2010303363B2 (en) Combination
EP2572199B1 (en) Combination
EP2485594B1 (en) Combination
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination
WO2014066202A1 (en) Combination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired